LA JOLLA, Calif.--(BUSINESS WIRE)--Novelix Pharmaceuticals Inc. (Novelix), a biopharmaceutical company focused on the development of first-in-class, small molecule cancer therapeutics, announced today that it successfully closed its Series A-3 Preferred Stock Financing allowing it to expand its team following its relocation from Pasadena, CA to La Jolla, CA.
